Intravitreal Triamcinolone for the Management of Macular Edema Dueto Nonischemic Central Retinal Vein Occlusion | Macular Diseases | JAMA Ophthalmology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.153.100.128. Please contact the publisher to request reinstatement.
1.
Weinberg  DV Venous occlusive disease of the retina. Albert  DMJakobiec  FAAzar  DT  et al. eds Principles and Practice of Ophthalmology. 2nd Philadelphia, Pa WB Saunders Co2000;1887- 1900Google Scholar
2.
The Central Vein Occlusion Study Group, Evaluation of grid pattern photocoagulation for macular edema in centralvein occlusion.  Ophthalmology. 1995;1021425- 1433PubMedGoogle ScholarCrossref
3.
Elman  MJRaden  RZCarrigan  A Intravitreal injection of tissue plasminogen activator for centralretinal vein occlusion.  Trans Am Ophthalmol Soc. 2001;99219- 221PubMedGoogle Scholar
4.
Opremcak  EMBruce  RALomeo  MRidnour  CDLeston  ADRehmar  AJ Radial optic neurotomy for central retinal vein occlusion.  Retina. 2001;21408- 415PubMedGoogle ScholarCrossref
5.
Weiss  JNBynoe  LA Injection of tissue plasminogen activator into a branch retinal veinin eyes with central retinal vein occlusion.  Ophthalmology. 2001;1082249- 2257PubMedGoogle ScholarCrossref
6.
McAllister  ILDouglas  JPConstable  IJYu  DY Laser-induced chorioretinal venous anastomosis for nonischemic centralretinal vein occlusion.  Am J Ophthalmol. 1998;126219- 229PubMedGoogle ScholarCrossref
7.
Jonas  JBKreissig  ISofker  ADegenring  RF Intravitreal injection of triamcinolone for diffuse diabetic macularedema.  Arch Ophthalmol. 2003;12157- 61PubMedGoogle ScholarCrossref
8.
Martidis  ADuker  JSGreenberg  PB  et al.  Intravitreal triamcinolone for refractory diabetic macular edema.  Ophthalmology. 2002;109920- 927PubMedGoogle ScholarCrossref
9.
Young  SLarkin  GBranley  MLightman  S Safety and efficacy of intravitreal triamcinolone for cystoid macularoedema in uveitis.  Clin Experiment Ophthalmol. 2001;292- 6PubMedGoogle ScholarCrossref
10.
Benhamou  NMassin  PHaouchine  BAudren  FTadayoni  RGaudric  A Intravitreal triamcinolone for refractory pseudophakic macular edema.  Am J Ophthalmol. 2003;135246- 249PubMedGoogle ScholarCrossref
11.
Ip  MSKumar  KS Intravitreous triamcinolone acetonide as treatment for macular edemafrom central retinal vein occlusion.  Arch Ophthalmol. 2002;1201217- 1219PubMedGoogle ScholarCrossref
12.
Greenberg  PBMartidis  ARogers  AHDuker  JSReichel  E Intravitreal triamcinolone acetonide for macular oedema due to centralretinal vein occlusion.  Br J Ophthalmol. 2002;86247- 248PubMedGoogle ScholarCrossref
13.
Wilson  CABerkowitz  BASato  Y  et al.  Treatment with intravitreal steroid reduces blood-retina barrier breakdowndue to retinal photocoagulation.  Arch Ophthalmol. 1992;1101155- 1159PubMedGoogle ScholarCrossref
14.
Conway  MDCanakis  CLivir-Rallatos  CPeyman  GA Intravitreal triamcinolone acetonide for refractory chronic psuedophakiccystoid macular edema.  J Cataract Refract Surg. 2003;2927- 33PubMedGoogle ScholarCrossref
15.
Funatsu  HYamashita  HNoma  HMimura  TYamashita  THori  S Increased levels of vascular endothelial growth factor and interleukin-6in the aqueous humor of diabetics with macular edema.  Am J Ophthalmol. 2002;13370- 77PubMedGoogle ScholarCrossref
16.
Pe'er  JFolberg  RItin  AGnessin  HHemo  IKeshet  E Vascular endothelial growth factor upregulation in human central retinalvein occlusion.  Ophthalmology. 1998;105412- 416PubMedGoogle ScholarCrossref
17.
Antcliff  RJMarshall  J The pathogenesis of edema in diabetic maculopathy.  Semin Ophthalmol. 1999;14223- 232PubMedGoogle ScholarCrossref
18.
Ozaki  HHayashi  HVinores  SAMoromizato  YCampochiaro  PAOshima  K Intravitreal sustained release of VEGF causes retinal neovascularizationin rabbits and breakdown of the blood-retinal barrier in rabbits and primates.  Exp Eye Res. 1997;64505- 517PubMedGoogle ScholarCrossref
19.
Fischer  SRenz  DSchaper  WKarliczek  GF In vitro effects of dexamethasone on hypoxia-induced hyperpermeabilityand expression of vascular endothelial growth factor.  Eur J Pharmacol. 2001;411231- 243PubMedGoogle ScholarCrossref
20.
Nauck  MKarakiulakis  GPerruchoud  APPapakonstantinou  ERoth  M Corticosteroids inhibit the expression of the vascular endothelialgrowth factor gene in human vascular smooth muscle cells.  Eur J Pharmacol. 1998;341309- 315PubMedGoogle ScholarCrossref
21.
Aiello  LPBursell  SEClermont  A  et al.  Vascular endothelial growth factor-induced retinal permeability ismediated by protein kinase C in vivo and suppressed by an orally effectivebeta-isoform-selective inhibitor.  Diabetes. 1997;461473- 1480PubMedGoogle ScholarCrossref
22.
Benz  MSMurray  TGDubovy  SRKatz  RSEifrig  CW Endophthalmitis caused by mycobacterium chelonae abscessus after intravitrealinjection of triamcinolone.  Arch Ophthalmol. 2003;121271- 273PubMedGoogle ScholarCrossref
23.
Challa  JKGillies  MCPenfold  PLGyory  JFHunyor  ABBilson  FA Exudative macular degeneration and intravitreal triamcinolone.  Aust N Z J Ophthalmol. 1998;26277- 281PubMedGoogle ScholarCrossref
Clinical Sciences
August 2004

Intravitreal Triamcinolone for the Management of Macular Edema Dueto Nonischemic Central Retinal Vein Occlusion

Author Affiliations

From the Departments of Ophthalmology, American University of Beirut–MedicalCenter, Beirut (Drs Bashshur, Ma'luf, Allam, Haddad, and Noureddin), and theAin Wa Zein Hospital, Shouf (Dr Jurdi), Lebanon. The authors have no relevantfinancial interest in this article.

Arch Ophthalmol. 2004;122(8):1137-1140. doi:10.1001/archopht.122.8.1137
Abstract

Objective  To evaluate the efficacy of intravitreal triamcinolone acetonide inthe management of persistent macular edema secondary to nonischemic centralretinal vein occlusion (CRVO).

Methods  Twenty consecutive patients were selected with a 3- to 4-month historyof nonischemic CRVO and persistent macular edema. These patients receiveda single intravitreal injection of 4 mg of triamcinolone acetonide (40 mg/mL).The follow-up period ranged from 10 to 12 months. The amount of macular edemawas assessed by the amount of retinal thickening on clinical examination usingthe Goldmann contact lens and by the area and intensity of staining on fluoresceinangiography. Treated patients were compared with a retrospectively matchedgroup of patients who were managed with observation only.

Main Outcome Measures  Changes in visual acuity and amount of macular edema were assessed inthe treated patients and compared with the observation group.

Results  The mean baseline visual acuity in the treatment group was 20/132 vs20/123 for the observation group (P = .57). After1 week, the treated group had a mean visual acuity of 20/51. At final follow-up,the treated group had a mean visual acuity of 20/37 while the observationgroup had a mean visual acuity of 20/110 (P = .001).Sixty percent of treated patients had a final visual acuity of 20/40 or bettervs only 20% in the observation group (P = .01). Fortypercent of the untreated patients had a final visual acuity worse than 20/200while none of the treated patients did (P<.001).At final follow-up, 75% of treated patients had complete resolution of macularedema on clinical examination vs only 20% of the untreated patients (P<.001). Two of the treated patients had recurrenceof macular edema at 6 months, and 3 had elevated intraocular pressure.

Conclusion  This study shows a treatment benefit from intravitreal triamcinolonein terms of visual acuity and macular edema for nonischemic CRVO.

×